Vinodh Jeevanantham, MD
Cardiovascular Disease · Oklahoma City, OKNPI 1174662308
Payments from drug & device makers
What this record shows
19 manufacturers reported payments, led by Edwards Lifesciences at 50.4% of the total.
Across 118 payments — averaging $95.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Boston Scientific$2K
- Medtronic$2K
- Abbott$899
- Abiomed$242
- Teleflex LLC$145
- plus $683 from 13 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Travel & lodging$5,68350%
- Food & beverage$5,64250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 32 | $5,707 |
| Boston Scientific | 14 | $1,873 |
| Medtronic(2 entities) | 28 | $1,777 |
| Abbott | 10 | $899 |
| Abiomed | 3 | $242 |
| Teleflex LLC | 1 | $145 |
| Novartis | 7 | $110 |
| Philips North America LLC | 5 | $104 |
| E.r. Squibb & Sons, L.L.C. | 4 | $99 |
| Atricure, Inc. | 2 | $83 |
| Asahi Intecc USA, Inc. | 1 | $75 |
| Heartflow, Inc. | 1 | $54 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $32 |
| Surmodics, Inc. | 3 | $31 |
| Chiesi USA, Inc. | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Inari Medical, Inc. | 1 | $18 |
| Cardiva Medical, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,325 in reported general payments places this provider in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 486 | $510,324 |
| EntrestoSacubitril/Valsartan | 133 | $148,839 |
| XareltoRivaroxaban | 43 | $45,476 |
| BrilintaTicagrelor | 52 | $42,803 |
| FarxigaDapagliflozin Propanediol | 17 | $22,978 |
| JardianceEmpagliflozin | 21 | $21,632 |
| Metoprolol Succinate | 685 | $8,486 |
| ClopidogrelClopidogrel Bisulfate | 514 | $7,416 |
| Atorvastatin Calcium | 555 | $6,880 |
| Ranolazine ErRanolazine | 31 | $6,532 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 369 | $4,372 |
| Amiodarone Hcl | 110 | $4,300 |
| Amlodipine Besylate | 474 | $3,248 |
| Carvedilol | 405 | $3,208 |
| Losartan Potassium | 269 | $2,935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $110 | $148,839133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Oklahoma City
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Udho ThadaniOklahoma City$41K
- Robert SullivanOklahoma City$36K
- Reji PappyOklahoma City$25K
- Sandeep ChopraOklahoma City$15K
- Jered CookOklahoma City$14K
- William CollazoOklahoma City$11K
- Niraj PrasadOklahoma City$10K
- Jeffrey AsburyOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.